Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer
Alectinib after ICI was associated with higher risks of pneumonitis and rash, and numerically higher risk of grade ≥3 hepatotoxicity, leading to increased rates of alectinib interruption and steroid use. These findings underscore the importance of expedited genotyping to guide treatment selection and avoid unwarranted ICI exposure.
Authors
- Jennifer Peterson (ORCID: https://orcid.org/0000-0001-7458-1504)
- Sarah Waliany (ORCID: https://orcid.org/0000-0001-5960-8801)
- Andrew Do (ORCID: https://orcid.org/0000-0002-5782-5818)
- W. Marston Linehan (ORCID: https://orcid.org/0000-0001-7373-3916)
- Anqi Liu (ORCID: https://orcid.org/0000-0002-3744-1585)
- Jiaxin Liang (ORCID: https://orcid.org/0000-0003-2129-3626)
- Justin Matthew Cheung
- B.Y. Yeap
Institutions
- Mass General Brigham (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105842
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52